Thu, Aug 1, 9:03 PM (340 days ago)
Supernus Pharmaceuticals, Inc. announced the resubmission of its New Drug Application (NDA) for SPN-830, an apomorphine infusion device aimed at treating motor fluctuations in Parkinson’s disease patients. This significant corporate event was disclosed in a press release dated August 1, 2024, and is included as Exhibit 99.1 in the filing. The company highlighted that the forward-looking statements contained in the report are subject to risks and uncertainties, as detailed in their Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The announcement may influence the company's financial position and stock value, as the successful approval of SPN-830 could enhance its market presence in the neurological treatment sector.